LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial - PACE-CME

LDLc lowering with twiceayear injection of siRNA against PCSK The ORION trial

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Biochemical urine test to measure medical adherence in hypertension
Biochemical urine test to measure medical adherence in hypertension
ESC 2019
Biochemical urine test to measure medical adherence in hypertension
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
ESC 2019
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
- Prof. François Mach, MD
Sex-related differences in ACS patients
Sex-related differences in ACS patients
ESC 2019
Sex-related differences in ACS patients
- Sanne Peters, PhD
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
ESC 2019
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
- Jan Westerink, MD, PhD